CAMBRIDGE, Mass. – Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal...
Latest News
HUNTSVILLE, Alabama — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the advancement of its novel product candidate, SER-270, a proprietary POZ-conjugated vesicular monoamine transporter 2 (VMAT2) inhibitor in development for the treatment of tardive dyskinesia (TD). SER-270,...
WALTHAM, Mass. — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that AstraZeneca Seroquel’s first-line patient share grew two percent since last year’s patient-level claims data analysis of prescribing trends in bipolar disorder. During this same time period other atypicals...
MUNCIE — Christopher Burrows got the best possible treat last Halloween. That’s the day he and his mother, Claudia Burrows, brought home Stitch, the service dog they’d been working toward for the past year. Claudia has ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease, while Christopher has autism...
BOSTON, MASS. — Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) glioma following surgical intervention and for whom chemoradiotherapy can be delayed were published in The Lancet Oncology. The analysis reports an additional six months of...
BOSTON, Mass. — Servier today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of VORANIGO® (vorasidenib) in the European Union (EU) for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1)...
VALENCIA, Calif. — SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS). Breakthrough...
Linköping, Sweden – A combination of only 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals. The identified proteins could be used to tailor treatments to the individual based on the expected severity of the disease. The study, led by researchers at Linköping University in...
It’s a warm Tuesday afternoon and the Shalvey family is enjoying the sun out on their patio while their dogs, Sam and Jerry, run around the yard. Add in their white picket fence and the image is idyllic – but not uncommon for Bill and Lynne and their two daughters,...
Sharjah, United Arab Emirates – Scientists from the University of Sharjah have found that a naturally growing aromatic plant contains ingredients with the ability to treat colorectal cancer. The plant is a common herb. It is scientifically known as Artemisia herba-alba. It grows naturally in North Africa and the Middle...